17/02/2026
The Australasian Dermatology Registry is conducting a study to determine the two-year drug survival rate of deucravacitinib (Sotyku), an oral TYK2 inhibitor used for treating psoriasis.
While clinical trials have shown deucravacitinib to be effective and safe, real-world data are still limited. This study will help understand the long-term effectiveness, identify factors influencing drug survival, and assess potential adverse events.
📅 Results will be presented at the Australasian College of Dermatologists Annual Scientific Meeting in May 2027.
🔗 Register Your Interest today and contribute to advancing psoriasis treatment: https://australasiandermatologyregistry.org.au/register-your-interest/
This study is proudly funded by Bristol Myers Squibb.
To learn more about the ADR and how to get involved, visit the link below.
https://australasiandermatologyregistry.org.au/